16 results about "Glutamine synthetase" patented technology

The invention discloses a molybdenum oxide nanorod material, a preparation method of the molybdenum oxide nanorod material and application of the molybdenum oxide nanorod material to improvement of corn nutrient utilization, growth promotion and lodging resistance, and belongs to the technical field of corn nutrient utilization and agricultural nano material application. The morphology and dispersity of the nanorod are optimized by combining molecular composition characteristics of key enzymes (such as nitrate reductase and glutamine synthetase) in a corn nutrient utilization process, and finally the functional nanorod with targeting property and biocompatibility is obtained and can be widely applied to nutrient regulation and control scenes of corn water culture and field planting. After the material is applied, the activity of nitrate reductase and glutamine synthetase of a corn root system can be activated in a targeted manner, the nutrient utilization efficiency is accurately improved, and sufficient nutrition support is provided for plant growth. After the fertilizer is applied to plants, the root system is promoted to be developed, the stalks are thick and strong, the lodging resistance is remarkably enhanced, the protein content of the plants and grains can be increased, and the synergistic effects of efficient nutrient utilization, robust plant growth, lodging resistance and yield increase are achieved.

The application discloses a novel double-carrier expression system for protein expression and a construction method and application thereof. The novel double-carrier expression system for protein expression comprises a first carrier containing a nucleotide sequence for coding a first functional domain of glutamine synthetase and a nucleotide sequence of light chain and heavy chain of a protein to be expressed; and a second carrier containing a nucleotide sequence for coding a second functional domain of glutamine synthetase and a nucleotide sequence of a ScFv sequence of the protein to be expressed, and an amino acid sequence of the glutamine synthetase is composed of the first functional domain and the second functional domain. By using the expression system, the transfection efficiency and screening efficiency are greatly improved, and the expression amount of the target protein is obviously increased.

The present disclosure relates to an L-arginine-producing microorganism in which the activity of a regulator of nitrate reductase operon expression is attenuated and the activity of glutamine synthetase is enhanced, and to a method for producing L-arginine using same, wherein the L-arginine-producing microorganism, in which the activity of the regulator of nitrate reductase operon expression is attenuated and the activity of glutamine synthetase is enhanced, has been confirmed to exhibit increased L-arginine production capability compared to a parent strain, and thus can be widely used for L-arginine production.

Systems and methods for producing ammonia are described. In one embodiment, hydrogen, carbon dioxide, and nitrogen are dissolved in a solution. A glutamine synthetase inhibitor and autotrophic diazotroph bacteria are also placed in the solution.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The invention discloses a glutamine synthetase (GS) mutant protein as well as a mutant gene and application thereof. According to the rice GS A2N mutant disclosed by the invention, the glufosinate-ammonium tolerance concentration of rice wild type GS can be improved by about 25 times while the enzyme activity is improved; according to the combined mutant rice GS A2N Y158C mutant, the glufosinate-ammonium tolerance concentration of rice wild type GS can be improved by about 150 times while the enzyme activity is improved by about 2 times, and transgenic rice can tolerate glufosinate-ammonium treatment with 4 times of field recommended dosage. After corresponding homologous sites are mutated, GS mutant transgenic plants of wheat, corn, soybean and rape can also tolerate treatment of glufosinate-ammonium with 4 times of recommended dosage in the field.

Glutamine synthetase mutant having glufosinate ammonium resistance, application thereof and a cultivation method therefor. Comparing with the reference sequence, the amino acid sequence of the glutamine synthetase mutant has one or a combination of the following mutations: (1) the amino acid of the glutamine synthetase mutant corresponding to amino acid site 59 of the reference sequence is mutated to X1, wherein X1=A, C, D, E, F, G, H, I, K, P, T, V or Y; (2) the amino acid of the glutamine synthetase mutant corresponding to amino acid site 296 of the reference sequence is mutated to X2, wherein X2=A, D, E, G, I, K, M, P, Q, R, S, T, or V.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

A transgenic soybean event, Gm_CSM63714, is provided. Transgenic plant cells, plant parts, plants, seeds, progeny plants, and agricultural and commodity products containing event Gm_CSM63714 are also provided. Recombinant DNA molecules unique to the event Gm_CSM63714, and methods of using and detecting Gm_CSM63714 are also provided. Soybean plants containing the event Gm_CSM63714 exhibit tolerance to benzoic acid auxins such as dicamba; phenoxy auxins such as 2,4-D; inhibitors of glutamine synthetase such as glufosinate; and P-triketone inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPPD) such as mesotrione.

A herbicidal composition and a method for controlling weeds, including one or more uracil compounds of formula (I) and a compound of formula (II), and a herbicide compound of group B and a safener of group C. A weight ratio of the uracil compounds to the herbicide compound group B and the safener group C is 1:0.02 to 1:50, and the herbicide compound of group B is one or more of compounds B-1 to B-12: B-1, acetolactate synthase inhibitors; B-2, acetyl CoA carboxylase inhibitors; B-3, protoporphyrinogen IX oxidase inhibitors; B-4, 4-hydrophenylpyrubic acid dioxygenase inhibitors; B-5, phytoene desaturase inhibitors; B-6, photosystem II inhibitors; B-7, very-long-chain fatty acid synthesis inhibitors; B-8, microtubule formation inhibitors; B-9, auxin-type herbicides; B-10, enolpyruvylshikimate-3-phosphate synthase inhibitors; B-11, glutamine synthase inhibitors; and B-12, other herbicides; or agriculturally acceptable salts or derivatives thereof

The application discloses application of glutamine synthetase inhibitors in preparation of antitumor drugs and belongs to the field of biological medicines. The CRISPR-Cas9 technology is used to knock out glutamine synthetase (sgRNA), compared with shRNA, permanent gene knockout can be introduced, and the application has the potential as a drug for treating colorectal cancer. The application targets glutamine synthetase for treatment on the basis of cancer chemotherapy drugs, significantly improves the sensitivity of tumor cells to chemotherapy drugs, and reduces the cell survival rate. The application of the targeted glutamine synthetase and the neutralizing antibody of alphaPD-L1 combined treatment can significantly enhance the antitumor immune response and improve the treatment efficiency.

The application provides a nuxvomica optimum form high-quality composite microbial inoculant and a use method, and belongs to the technical field of plant cultivation. The application provides a composite microbial inoculant for inhibiting the formation of lateral roots of nuxvomica seedlings, which comprises Weizmannia coagulans and Brevibacillus parabrevis, and mainly improves the content of salicylic acid, reduces the content of 1-aminocyclopropane-1-carboxylic acid (a precursor of ethylene synthesis) and ICA (an auxin), improves the activities of peroxidase and glutamine synthetase and the content of total phenol of plants, improves the contents of soil urease, polyphenol oxidase and alkaline hydrolyzable nitrogen, reduces the contents of available potassium and total phenolic acid, and promotes the conversion of ammonium nitrogen to nitrate nitrogen, so that the formation of lateral roots of nuxvomica is inhibited, the nitrogen content of the roots of nuxvomica seedlings is improved, the disease resistance is improved, and the breeding of optimum form and high-quality seedlings is promoted.

The present application relates to the technical field of genetic engineering, and particularly relates to a recombinant microorganism and application thereof in amino acid production. The present application provides a new glutamine synthetase mutant, which can significantly improve the production capacity of bacteria for threonine and other amino acids. Based on the mutant, the present application constructs a recombinant microorganism expressing the glutamine synthetase mutant, and the threonine yield and conversion rate of the recombinant microorganism are significantly improved compared with a starting strain. The glutamine synthetase mutant and the recombinant microorganism provided by the present application have good application prospects in the field of microbial fermentation.

The invention relates to the technical field of microorganisms, and discloses a paenibacillus engineering strain PG97 as well as a construction method and application thereof, a point mutation engineering strain PG97 is obtained through site-specific mutagenesis of glnA genes of paenibacillus, a mutant PGlnA-P97L (PG97) is obtained by replacing a 97th proline codon (CCG) of glutamine synthetase encoded by the point mutation engineering strain PG97 with a leucine codon (CTG), and the mutant PGlnA-P97L (PG97) is obtained by the construction method of the paenibacillus engineering strain PG97. The mutant keeps nitrogenase activity under the ammonium concentration of 0-100 mM, and breaks through the inhibition effect of high-concentration ammonium on biological nitrogen fixation; meanwhile, the extracellular ammonium secreting capacity is remarkably improved, more effective nitrogen sources are provided for plants, the growth promoting effect on cucumbers and rice is improved, and wide application prospects are achieved in the field of agricultural production.

The present application relates to a microorganism into which an exogenous glutamine synthetase has been introduced and a method for producing L-tryptophan using the same.